Unexpected acute renal injury after high-dose etoposide phosphate and total body irradiation in children undergoing hematopoietic stem cell transplantation.

Date publication

juillet 2017

Journal

Pediatric blood & cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr CHASTAGNER Pascal , Dr POCHON Cécile

Tous les auteurs :
Cordero C, Loboda C, Clerc-Urmès I, Clément L, Pochon C, Chastagner P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28696051

Résumé

High-dose etoposide phosphate, a water-soluble prodrug of etoposide, may be used after total body irradiation (TBI) in pediatric allogeneic bone marrow transplantation for lymphoblastic leukemia. In a retrospective study of 21 children treated at the Nancy University Hospital (2000-2014), we identified unprecedentedly an unexpectedly high incidence (57%) of acute renal injury following etoposide phosphate infusion. Patients who developed renal function impairment experienced more severe mucositis but had outcomes similar to those who did not. No risk factors were identified. We speculate that the etoposide phosphate diluent, dextran 40, may have been the causative agent in these post-TBI renal toxicity cases.

Mots clés

ALL, chemotherapy, general hematology/oncology, pharmacology, renal complications after BMT, transplantation

Référence

Pediatr Blood Cancer. 2017 Jul;: